Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants

NCT01218451 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT01218451
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01218451 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3b, Randomized, Open Label, Feasibility Study of a Single Priming Dose of Meningococcal Group C Conjugate Vaccine (NeisVac-C) in Infants
Lead sponsor
Pfizer
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2010
Completion date
June 30, 2012
Enrollment
956 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

neisseria meningitidis